The global infertility drugs market is expected to grow at a CAGR of 6.20% in the forecast period of 2023-2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The gonadotrophins segment based on drug class accounts for a significant share in the market owing to the ability of gonadotrophins to ameliorate the chances of women being pregnant. A single gonadotrophin injection can stimulate the ovaries of women to produce follicles, which contain egg.
In addition to this, women are becoming more aware about reduced side-effects associated with gonadotrophins. Hence, the segment accounts for a significant share in the market and is expected to witness a considerable growth in the coming years.
According to a research study, there is an increase in the number of couples in North America and Europe who are trying to conceive and are facing the risk of infertility . This is mainly due to the hectic and busy lifestyles of people in countries like the United States and Canada. In some of the states in the US, insurance policies also cover the costs of infertility treatment. This is driving the growth of the infertility drugs industry in North America. In addition to this, the thriving pharmaceutical industry in the region, coupled with highly trained doctors in hospitals and clinics, is one of the key factors driving the market growth in the region.
Infertility drugs are drugs that are used to boost fertility among men and women who have difficulty getting pregnant. Infertility drugs are usually prescribed by doctors to stimulate ovulation in women and promote the production of healthy sperm among men.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug class, the market can be segmented into:
The significant end users of the product include:
The segmentation of the market, on the basis of distribution channel, is as follows:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global infertility drugs industry is driven by the rising cases of infertility globally, or difficulty carrying a pregnancy to term. Certain medical conditions among men and women, such as diabetes, cystic fibrosis, testicular failure, hormonal disorders, menopausal disorders, urinary infections, endometriosis, pelvic inflammatory disease (PID), and ovarian cysts, among others, can lead to infertility. The surge in the cases of these disorders can be attributed to unhealthy lifestyles and changing dietary habits, including smoking, anabolic steroid use, stress, obesity, and others, thereby contributing to the demand for infertility drugs . In addition, the market is anticipated to be supported by the development of advanced infertility treatment laboratories in emerging economies owing to the increased healthcare expenditure by the governments. This is expected to aid the market in the forecast period.
The report gives a detailed analysis of the following key players in the global infertility drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter’s five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug Class||
|Breakup by Gender||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Infertility Drugs Market Overview
3.1 Global Infertility Drugs Market Historical Value (2016-2022)
3.2 Global Infertility Drugs Market Forecast Value (2023-2031)
4 Global Infertility Drugs Market Landscape
4.1 Global Infertility Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Infertility Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Gender
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Distribution Channel
5 Global Infertility Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Infertility Drugs Market Segmentation
6.1 Global Infertility Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Clomiphene Citrate
6.1.4 Aromatase Inhibitors
6.1.5 Selective Estrogen Receptor Modulators (SERMs)
6.1.6 Dopamine Agonists
6.2 Global Infertility Drugs Market by Gender
6.2.1 Market Overview
6.3 Global Infertility Drugs Market by Route of Administration
6.3.1 Market Overview
6.4 Global Infertility Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Retail Pharmacy
6.4.4 Online Pharmacy
6.5 Global Infertility Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Infertility Drugs Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Infertility Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Infertility Drugs Market
9.1 Market Share by Country
10 Latin America Infertility Drugs Market
10.1 Market Share by Country
11 Middle East and Africa Infertility Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Supplier Landscape
18.1 Merck KGaA
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Abbott Laboratories
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Mankind Pharma
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5 Ferring Pharmaceuticals Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Thermo Fisher Scientific, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7 Genea Biomedx
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 IVFtech ApS
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
19 Global Infertility Drugs Market - Distribution Model (Additional Insight)
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is estimated to grow at a CAGR of 6.20% between 2023 and 2028.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the industry, such as the rising cases of infertility among men and women, improving healthcare facilities, growing awareness, and the establishment of advanced infertility treatment laboratories, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the growing FDA approval of new and efficient infertility drugs.
Gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), and biguanides, among others are the different segments based on drug class.
Male and female are the different end users considered within the market report.
Hospital pharmacies and retail pharmacies, among others are the different distribution channels of infertility drugs.
The major players in the industry are Merck KGaA, Abbott Laboratories, Mankind Pharma, Pfizer Inc., and Ferring Pharmaceuticals Inc., among others.
The global infertility drugs market is being driven by the rising cases of infertility among men and women. Aided by the rising investments to develop advanced infertility treatment laboratories, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 6.20%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug class, the market is divided into gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), and biguanides, among others. On the basis of end user, the market is divided into male and female. The major distribution channels of the product are hospital pharmacies and retail pharmacies, among others. The major regional markets for infertility drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Merck KGaA, Abbott Laboratories, Mankind Pharma, Pfizer Inc., and Ferring Pharmaceuticals Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.